NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 245 filers reported holding NEKTAR THERAPEUTICS in Q1 2020. The put-call ratio across all filers is 1.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $31,000 | -39.2% | 1,425 | -49.5% | 0.00% | 0.0% |
| Q3 2019 | $51,000 | -62.5% | 2,823 | -26.0% | 0.00% | -50.0% |
| Q2 2019 | $136,000 | +3.8% | 3,816 | -2.0% | 0.00% | 0.0% |
| Q1 2019 | $131,000 | -0.8% | 3,892 | -2.9% | 0.00% | -33.3% |
| Q4 2018 | $132,000 | -77.6% | 4,007 | -58.6% | 0.00% | -70.0% |
| Q3 2018 | $589,000 | +57.9% | 9,670 | +26.7% | 0.01% | +66.7% |
| Q2 2018 | $373,000 | – | 7,633 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |